Effects of tachyplesin I on human U251 glioma stem cells
Hong Ding1, Gang Jin2, Lijun Zhang2
1Faculty of Chemical Engineering and Light Industry, Guangdong University of Technology, Guangzhou, Guangdong 510006, P.R. China.
Abstract:
Glioblastoma, is one of the most malignant types of intracranial tumor with complex progressive cellular and underlying molecular events. The use of glioma stem cells (GSCs) offers a promising strategy for tumor therapy in the future. Tachyplesin I has been demonstrated to have potential anticancer activity and was first observed in leukocytes. In the present study, the GSC subset was isolated from U251 glioma cells and tachyplesin I was assessed for antitumor activity. As a result, the U251 cells exhibited certain GSC phenotypes, including the expression of stem cell biomarkers CD133 and nestin, when transferred into stem cell culture conditions. The GSCs were grown in an adherent manner in a medium containing serum, while the U251 glioma cells were suspended and cultured in serum‑free medium. Tachyplesin I damaged the structure of GSC and inhibited the culture of GSC spheres in a time and dose‑dependent manner. When tachyplesin I was administered at a concentration of 10‑40 µg/ml, GSC differentiation was induced. GSCs treated with a low dose of tachyplesin I disrupted the plasma membrane and led to a loss of cytoplasmic organelles. These findings indicated that tachyplesin I had an effect on inhibiting tumor stem cells and demonstrated that tachyplesin I inhibited GSCs by disrupting the plasma membranes and inducing GSC differentiation.
Insights
Tachyplesin I effectively inhibits glioma stem cells (GSCs) by damaging their structure and inducing differentiation. This study highlights Tachyplesin I
Area of Science:
- Oncology
- Cell Biology
- Biochemistry
Background:
- Glioblastoma is a highly malignant brain tumor.
- Glioma stem cells (GSCs) are a key therapeutic target.
- Tachyplesin I shows potential anticancer properties.
Purpose of the Study:
- To investigate the antitumor activity of Tachyplesin I against GSCs.
- To determine the mechanism of Tachyplesin I's action on GSCs.
Main Methods:
- Isolation of GSCs from U251 glioma cells.
- Culture of GSCs under specific conditions.
- Treatment of GSCs with varying concentrations of Tachyplesin I.
- Microscopic analysis of GSC structural changes and differentiation.
Main Results:
- U251 cells cultured in stem cell conditions exhibited GSC phenotypes (CD133+, nestin+).
- Tachyplesin I inhibited GSC sphere culture in a time- and dose-dependent manner.
- Tachyplesin I disrupted GSC plasma membranes and induced GSC differentiation at 10-40 µg/ml.
Conclusions:
- Tachyplesin I demonstrates significant inhibitory effects on GSCs.
- The mechanism involves plasma membrane disruption and induced GSC differentiation.
- Tachyplesin I represents a potential therapeutic agent for glioblastoma.
